You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Dabrafenib

Showing 26 - 50 of 171
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Melanoma Trial in Boston (MCS110, Dabrafenib, Trametinib)

Active, not recruiting
  • Melanoma
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Dec 14, 2022

Patients With Completely Resected High-risk Stage III Melanoma.

Recruiting
  • Melanoma
  • Bursa, Gorukle, Turkey
  • +9 more
Feb 28, 2022

Metastatic Melanoma Trial in Darlinghurst, Sydney, Brisbane (Palliative radiotherapy, Dabrafenib and trametinib (combination))

Completed
  • Metastatic Melanoma
  • Palliative radiotherapy
  • Dabrafenib and trametinib (combination)
  • Darlinghurst, New South Wales, Australia
  • +2 more
Apr 6, 2022

Melanoma Trial in Boston (Trametinib, Dabrafenib, INCB039110)

Active, not recruiting
  • Melanoma
  • Boston, Massachusetts
    Massachusetts General Hospital
Nov 1, 2021

Anaplastic Thyroid Cancer Trial in Leiden (dabrafenib/trametinib)

Recruiting
  • Anaplastic Thyroid Cancer
  • Leiden, Zuid-Holland, Netherlands
    Ellen Kapiteijn
Oct 5, 2023

Melanoma Trial in Louisville (Dabrafenib, Trametinib, Metformin)

Recruiting
  • Melanoma
  • Dabrafenib
  • +2 more
  • Louisville, Kentucky
  • +1 more
Oct 22, 2021

Advanced BRAF Mutant Melanoma Trial in United States (Trametinib 2 mg daily, hydroxychloroquine (HCQ), dabrafenib 150 mg orally

Completed
  • Advanced BRAF Mutant Melanoma
  • Trametinib 2 mg daily
  • +2 more
  • Chicago, Illinois
  • +3 more
Jan 18, 2022

Cancer, Melanoma Trial in Worldwide (Dabrafenib, Trametinib)

Completed
Has Results
  • Cancer
  • Melanoma
  • Guangzhou, Guangdong, China
  • +12 more
Jan 4, 2022

Low Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration, Low Grade

Recruiting
  • Low Grade Glioma (LGG) of Brain With BRAF Aberration
  • +2 more
  • Dabrafenib
  • +2 more
  • Phoenix, Arizona
  • +12 more
Apr 7, 2022

BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma

Active, not recruiting
  • Melanoma
  • Dabrafenib and Trametinib
  • Buxtehude, Niedersachsen, Germany
  • +35 more
Aug 25, 2022

metAsTatI? melanOma Treated With dabrafeNib and trAmetinib in

Recruiting
  • Melanoma Stage III
  • +2 more
  • Barnaul, Alatai, Russian Federation
  • +14 more
May 29, 2022

NSCLC, BRAF V600 Mutation, MET Exon 14 Mutation Trial in Guangzhou (Dabrafenib + Trametinib, Capmatinib)

Not yet recruiting
  • NSCLC
  • +2 more
  • Guangzhou, Guangdong, China
    Cancer Center of Sun-Yat Sen University
Sep 19, 2023

Differentiated Thyroid Cancer Trial in Worldwide (Dabrafenib, Trametinib, Trametinib )

Recruiting
  • Differentiated Thyroid Cancer
  • Dabrafenib
  • +3 more
  • Caba, Buenos Aires, Argentina
  • +41 more
Nov 25, 2022

Melanoma Trial in Italy (dabrafenib, Trametinib)

Recruiting
  • Melanoma
  • Meldola, Forlì-Cesena, Italy
  • +15 more
Mar 18, 2022

Advanced Cancer, Solid Tumor Trial in Helsinki, Kuopio, Tampere (Alectinib, Cobimetinib, Vismodegib)

Recruiting
  • Advanced Cancer
  • Solid Tumor
  • Helsinki, Uusimaa, Finland
  • +2 more
Jun 8, 2022

Cancer Trial in Melbourne (Trametinib, Cobimetinib, Binimetinib)

Recruiting
  • Cancer
  • Melbourne, Victoria, Australia
    Peter MacCallum Cancer Centre
Nov 4, 2022

BRAF V600E Mutation Trial run by the NHGRI (Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide)

Completed
Has Results
  • BRAF V600E Mutation
  • Dabrafenib Mesylate
  • Trametinib Dimethyl Sulfoxide
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Aug 6, 2021

Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation Trial in Villejuif (Trametinib,

Active, not recruiting
  • Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
  • Villejuif, Val De Marne, France
    Gustave Roussy
Sep 27, 2021

Adverse Events-related Healthcare Resource Utilization and Costs

Completed
  • Melanoma
  • East Hanover, New Jersey
    Novartis Pharmaceuticals
Jan 27, 2023

Small Cell Lung Carcinoma Trial (Dabrafenib, Trametininb)

Available
  • Small Cell Lung Carcinoma
  • (no location specified)
Aug 20, 2021

Malignant Melanoma Trial in Herlev, Aarhus, Odense (Pembrolizumab Injection [Keytruda], Ipilimumab Injection [Yervoy], Nivolumab

Recruiting
  • Malignant Melanoma
  • Pembrolizumab Injection [Keytruda]
  • +6 more
  • Herlev, Hovedstaden, Denmark
  • +2 more
Sep 16, 2022

Pyrexia Trial in Zürich (Actemra)

Recruiting
  • Pyrexia
  • Zürich, Switzerland
    University Hospital Zurich, Clinic of Dermatology
Sep 29, 2021

Melanoma, Brain Metastases Trial in Canada (Dabrafenib, Trametinib)

Terminated
Has Results
  • Melanoma
  • Brain Metastases
  • Halifax, Nova Scotia, Canada
  • +5 more
Aug 18, 2021

BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Melanoma Trial in Boston (drug, biological, other)

Terminated
  • BRAF V600E Mutation Present
  • +7 more
  • Dabrafenib
  • +4 more
  • Boston, Massachusetts
  • +1 more
Mar 9, 2022

Melanoma Trial in Jette (Dabrafenib, Trametinib, Hydroxychloroquine)

Recruiting
  • Melanoma
  • Dabrafenib
  • +2 more
  • Jette, Brabant, Belgium
    UZ Brussel
Apr 27, 2021